Skip to main content
← All Tags

Clinical Trials

39 articles in this category (Page 1 of 2)

BiotechnologyEarningsClinical Trials

Immunovant (IMVT) May 20, 2026: Sideways Prediction with 5/10 Confidence Amid Overbought Conditions and Mixed Catalysts

Immunovant's strong IMVT-1402 data is offset by overbought RSI and no near-term catalysts, suggesting sideways trading.

IMVT
Read more
BiotechnologyClinical TrialsFinancial Analysis

Erasca, Inc. (ERAS) 21-Day Financial Prediction: Bullish Clinical Data vs. Severe Cash Burn

Preliminary Phase 1 data showing a 62% response rate for ERAS-0015 signals a potential upside, though severe cash burn risks remain.

ERAS
Read more
HealthcareBiotechnologyClinical Trials

Alumis Inc. (ALMS): Oversold Technicals and Positive Phase 3 Data Setup 21-Day Rebound

Deeply oversold technicals combined with recent positive Phase 3 psoriasis data suggest a near-term upward reversion for Alumis Inc.

ALMS
Read more
HealthcareBiotechnologyClinical Trials

Apogee Therapeutics (APGE): 5-Day Bullish Outlook Driven by Positive Phase 2 APEX Trial Data

Apogee Therapeutics is poised for short-term upside following highly positive 52-week Phase 2 data for zumilokibart and subsequent analyst price target hikes.

APGE
Read more
HealthcareBiotechnologyClinical Trials

Xenon Pharmaceuticals (XENE) 5-Day Outlook: Imminent Phase 3 Catalyst Clashes with Overbought Technicals

An impending Phase 3 data readout for azetukalner presents a massive binary catalyst, though extreme overbought technicals cap near-term upside confidence.

XENE
Read more
HealthcareClinical TrialsMarket Analysis

Novo Nordisk Faces Severe Headwinds Following CagriSema Trial Failure: 5-Day Bearish Outlook

Novo Nordisk's stock faces continued downward pressure after its weight-loss drug CagriSema missed trial goals against Eli Lilly, prompting a severe 2026 guidance cut.

NVO
Read more
Stock Weather AIBiotechClinical Trials

Apogee Therapeutics – 2026-01-23 - Increase Confidence 8/10

Negative free cash flow persists, but strong clinical catalysts and bullish analyst momentum signal near-term upside.

APGE
Read more
Stock Weather AIBiotechnologyClinical Trials

Moderna – 2026-01-21 - Increase Confidence 8/10

Negative free cash flow and high leverage offset by strong clinical catalysts and upward revenue guidance, driving near-term upside.

MRNA
Read more
Stock Weather AIBiotechnologyClinical Trials

Erasca, Inc. – 2026-01-15 - increase Confidence 8/10

Negative free cash flow is offset by $362.4M cash runway and recent positive clinical data for ERAS-0015, triggering analyst upgrades and technical bullishness, pointing to near-term price increase.

ERAS
Read more
Stock Weather AIBiotechnologyClinical Trials

Edgewise Therapeutics – 2026-01-14 - Increase Confidence 8/10

Strong cash position and positive trial data catalyze momentum; stock poised for near-term upside following J.P. Morgan Conference boost.

EWTX
Read more
Stock Weather AIBiotechnologyClinical Trials

Viking Therapeutics – 2026-01-14 - increase Confidence 8/10

Negative free cash flow offset by robust cash reserves and recent clinical trial milestones signal imminent upside from VK2735 data catalysts.

VKTX
Read more
Stock Weather AIBiotechnologyClinical Trials

Structure Therapeutics – 2026-01-13 - Increase Confidence 8/10

Negative free cash flow is offset by strong momentum and recent analyst upgrade, fueling near-term upside potential ahead of clinical data.

GPCR
Read more
Stock Weather AIBiotechnologyClinical Trials

Summit Therapeutics Inc. – 2026-01-12 - increase Confidence 7/10

Negative free cash flow and high leverage are outweighed by strong analyst momentum and Phase III trial expansion, signaling near-term upside.

SMMT
Read more
Stock Weather AIBiotechnologyClinical Trials

CG Oncology – 2026-01-09 - Increase Confidence 8/10

Strong cash position and recent positive trial data converge with upcoming J.P. Morgan Conference presentation to catalyze near-term upside.

CGON
Read more
Stock Weather AIBiotechnologyClinical Trials

Corcept Therapeutics – 2025-12-30 - Increase Confidence 8/10

Strong free cash flow and recent FDA acceptance of relacorilant for ovarian cancer signal near-term upside despite high valuation.

CORT
Read more
Stock Weather AIBiotechnologyClinical Trials

Ultragenyx Pharmaceutical – 2025-12-30 - Decrease Confidence 8/10

Negative free cash flow and sky-high debt/equity meet Phase III trial failure; stock poised to decrease despite short-term rally.

RARE
Read more
Stock Weather AIBiotechnologyClinical Trials

Belite Bio – 2025-12-29 - Increase Confidence 8/10

Strong cash position and recent positive Phase 3 trial results act as catalysts for near-term upside despite ongoing negative free cash flow.

BLTE
Read more
Stock Weather AIBiotechnologyClinical Trials

Edgewise Therapeutics – 2025-12-25 - Increase Confidence 8/10

Negative free cash flow contrasts with positive Phase 2 trial data for EDG-7500, triggering investor optimism and a near-term price catalyst for EWTX.

EWTX
Read more
Stock Weather AIBiotechnologyClinical Trials

Structure Therapeutics – 2025-12-23 - increase Confidence 8/10

Strong cash reserves and recent positive Phase 2 trial data for its oral weight loss drug aleniglipron signal near-term upside despite negative free cash flow.

GPCR
Read more
Stock Weather AIBiotechnologyClinical Trials

Edgewise Therapeutics – 2025-12-22 - Increase Confidence 7/10

Strong cash position and positive Phase 1/2 data for EDG-7500 converge with upcoming investor updates, signaling near-term upside potential.

EWTX
Read more
Stock Weather AIBiotechnologyClinical Trials

Zenas BioPharma – 2025-12-22 - Increase Confidence 8/10

Strong cash position and positive trial data converge ahead of imminent Phase 3 readout, signaling near-term upside for ZBIO.

ZBIO
Read more
Stock Weather AIBiotechnologyClinical Trials

Insmed – 2025-12-18 - Increase Confidence 6/10

Despite negative free cash flow and a failed Phase 2 trial, FDA approval of Brinsupri and strong analyst sentiment signal near-term upside potential.

INSM
Read more
Stock Weather AIBiotechnologyClinical Trials

Immunome – 2025-12-15 - increase Confidence 8/10

Positive Phase 3 trial data meets primary endpoint with high statistical significance, triggering revaluation despite negative free cash flow; stock poised for near-term upside.

IMNM
Read more
Stock Weather AIBiotechnologyClinical Trials

Wave Life Sciences – 2025-12-11 - Increase Confidence 8/10

Despite negative cash flow, a $250M capital raise and positive Phase 1 obesity drug data catalyze near-term upside momentum.

WVE
Read more